Intravascular Ultrasound for Hepatocellular Carcinoma Staging

The recruitment status of this study is unknown because the information has not been verified recently.

Verified May 2007 by University Hospital, Geneva.
Recruitment status was Recruiting

Sponsor:

Information provided by:

University Hospital, Geneva

ClinicalTrials.gov Identifier:

NCT00474734

First received: May 15, 2007

Last updated: May 16, 2007

Last verified: May 2007

History of Changes

Purpose

To diagnose hepatocellular carcinoma (HCC) and to determine the extent of the disease, a triphasic CT scan or a magnetic resonance imaging are required. The characterization of hepatic nodules is more difficult when the HCC lesions have a diameter of less than 2 cm.

Since accuracy in the assessment of the number and the size of HCC nodules, as well as of the invasion of blood vessels is crucial to determine outcome after liver transplantation due to tumour recurrence, there is a need for techniques with a higher definition potential.

As a consequence, to improve outcome and to optimize organ allocation, patients on the liver transplantation waiting list might benefit from intravascular ultrasound as an additional examination to complete the pre-transplant tumour staging process.

Condition	Intervention
Hepatocellular Carcinoma	Device: Intravascular ultrasound of the liver


Study Type:	Observational
Study Design:	Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Longitudinal
Official Title:	Intravascular Ultrasound for the Staging of Hepatocellular Carcinoma: a Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Ultrasound

Genetic and Rare Diseases Information Center resources: Liver Cancer

U.S. FDA Resources

Further study details as provided by University Hospital, Geneva:


Study Start Date:	May 2007
Estimated Study Completion Date:	September 2007

Eligibility


Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

hepatocellular carcinoma nodules
patient on liver transplantation waiting list
written informed consent

Exclusion Criteria:

thrombosis of hepatic veins or vena cava

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00474734

Contacts


Contact: Antoine Hadengue, Prof.	+41 22 37 29 340	antoine.hadengue@hcuge.ch

Locations


Switzerland
University Hospital Geneva	Recruiting
Geneva, Switzerland
Contact: Andrea De Gottardi, MD PhD +41 22 37 29 256 andrea.degottardi@hcuge.ch

Sponsors and Collaborators

University Hospital, Geneva

Investigators


Study Chair:	Antoine Hadengue, Prof.	University Hospital, Geneva

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00474734 History of Changes
Obsolete Identifiers:	NCT00472979
Other Study ID Numbers:	07-063
Study First Received:	May 15, 2007
Last Updated:	May 16, 2007
Health Authority:	Switzerland: Swissmedic

Keywords provided by University Hospital, Geneva:


hepatocellular carcinoma liver transplantation staging intravascular ultrasound

Additional relevant MeSH terms:


Carcinoma Carcinoma, Hepatocellular Adenocarcinoma Digestive System Diseases Digestive System Neoplasms Liver Diseases	Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on March 02, 2015

To Top